Support Material: Old Age, Dementia
PLEASE NOTE: The following documents have been donated by teams who are willing to share their experiences, expertise and knowledge. Please be aware that a considerable amount of time and effort has gone into the production of these documents and if you are planning to use them within your own organisation they should be referenced appropriately within your individual Trust Policies or Procedures. This is particularly important where the documents are copyright under intellectual copyright. If you are planning to use these documents in developing and producing work for any national or international organisation e.g. CSIP, NICE, National Prescribing Centre, Department of Health NIMHE etc. the author and/or organisation must be contacted to obtain their permission prior to use and where permission is given the correct attribution must be given.
- Risperidone and olanzapine in stroke/old age, Norfolk's suggestions for the CSM recommendation not to use risperidone and olanzapine in elderly people with behavioural problems in dementia (donated by Steve Bazire, March 2004)
- Risperidone and olanzapine in stroke/old age, Sussex's suggestions for the CSM recommendation not to use risperidone and olanzapine in elderly people with behavioural problems in dementia (donated by Ray Lyon from Sussex, April 2004)
- Risperidone and olanzapine in stroke/old age, South West Yorkshire's suggestions for the CSM recommendation not to use risperidone and olanzapine in elderly people with behavioural problems in dementia (donated by Lynn Haygarth, May 2004)
- Protocol for managed introduction of Alzheimers drugs (July 2001)
- Memantine evaluation, with cost, clinical benefits and disadvantages etc from Goodmayes (January 2003)
- Memantine evaluation (another), cost, clinical benefits and disadvantages etc from Maudsley (January 2003)